Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Sunday, September 28

3:10 PM - 3:20 PM PT

111 - Perioperative Chemotherapy Duration Affects the Survival of Locally Advanced Rectal Cancer: A Post-Hoc Analysis of a Multicenter Randomized, Phase III Trial
Speaker: Xu, Tongzhen, MD - Chinese Academy of Medical Science, Bejing, Beijing
3:10 PM - 3:20 PM PT

118 - Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:10 PM - 3:20 PM PT

131 - Gut Microbiota Predictive of Consolidation Immunotherapy Efficacy and Toxicity after Chemoradiotherapy in Lung Cancer
Speaker: Li, Yitong, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing, Beijing
3:10 PM - 3:20 PM PT

138 - Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Underlies Immune Evasion after Radiotherapy
Speaker: Kong, Lingyi, MD - Union Hospital Cancer Center, Tongji Medical College, HUST, Wuhan, Hubei
3:12 PM - 3:19 PM PT

1039 - Integration of Imaging and Blood-Based Biomarkers for Prognostication in Locally Advanced Cervical Cancer
Speaker: Rajan, Shrikiriti, MD - University of Iowa, Iowa City, IA
3:20 PM - 3:30 PM PT

105 - Use of Gadolinium Nanoparticles as Radiosensitizers for Brain Metastases: Results from the Phase 2 Multicentric Randomized Trial (NANORAD2)
Speaker: Verry, Camille, MD - Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, Isere
3:20 PM - 3:30 PM PT

112 - Efficacy and Safety of Short-Course Radiotherapy Followed By Sequential Chemotherapy and AK104 in Locally Advanced Rectal Cancer: Results from a Prospective, Multicenter Phase II Trial
Speaker: Xu, Tongzhen, MD - Chinese Academy of Medical Science, Bejing, Beijing
3:20 PM - 3:30 PM PT

119 - Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:20 PM - 3:30 PM PT

132 - Consolidative Radiotherapy with Osimertinib in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: Long-Term Local and Intracranial Control Results from a Phase II Trial
Speaker: Sampath, Sagus, MD - City of Hope Medical Center, Duarte, CA
3:20 PM - 3:30 PM PT

139 - Genomic and Transcriptomic Profiling of Radiation Resistant, Locally Recurrent Prostate Cancer
Speaker: Neilsen, Beth, MD, PhD - University of California Los Angeles, Los Angeles, CA
3:30 PM - 3:40 PM PT

106 - Prospective Interventional Study Investigating the Neurocognitive Effects and Quality of Life (QOL) in Patients with Brain Metastases, Comparing Hippocampal Avoidance Whole-Brain Radiation Therapy (HA-WBRT) with SIB to SRS/FSRT
Speaker: Das, Souvik Sankar, MBBS - Chittaranjan National Cancer Institute, Kolkata, West Benga
3:30 PM - 3:35 PM PT

120 - 5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy
Speaker: Ma, Mingwei, MD - Peking University First Hospital, Beijing, Beijing